Listing & Compliance Notices

Seer, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“July 7, 2025, Seer, Inc. (the "Company") notified The Nasdaq Stock Market LLC (“Nasdaq”) that following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), the Company will no longer be in compliance with the Nasdaq Listing Rule 5605(c)(2)(A), which requires that (i) the Audit Committee of the Company's Board of Directors (the “Audit Committee”) be composed of at least three members, and (ii) that one member of the Audit Committee has past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience”

Laser Photonics Corp received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“June 24, 2025, Nasdaq notified the Company that based on the June 23, 2025, filing of the Company’s Form 10-K for the fiscal year ended December 31, 2024, Nasdaq determined that the Company complies with the Rule and that this matter was now closed. On July 3, 2025, Nasdaq notified the Company that based on the July 3, 2025, filing of the Company’s Form 10-Q for the period ended March 31, 2025, Nasdaq has determined that the Company complies with the Rule and that this matter is now closed.”

SUNLINK HEALTH SYSTEMS INC received a nyse_american deficiency notice notice regarding shareholders.

“July 3, 2025, SunLink Health Systems, Inc., a Georgia corporation (“SunLink” or the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stockholders during the Company’s fiscal year ended June 30, 2025, as required by Section 704 of the NYSE American Company Guide (the “Company Guide”). A copy of the press release that discusses this matter is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The Notice has no immediate impact on the listing of the Company’s common”

Triller Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“e Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 29, 2025, in which to regain compliance. In order to regain compliance with the Minimum Bid Price Requirement, the cl”

Dragonfly Energy Holdings Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(2)).

“July 2, 2025, Dragonfly Energy Holdings Corp. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, based on the plan of compliance submitted by the Company, a Nasdaq Hearings Panel (the “Panel”) had granted the Company an exception until November 10, 2025 (the “Exception”) to regain compliance with (i) the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and (ii) the requirement to maintain a minimum market value of listed securities (“MVLS”) of $”

Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“July 2, 2025, the Panel notified the Company that it has granted Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement (the “Exception”). Pursuant to the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. The Company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement, including seeking shareholder approval for a r”

PETMED EXPRESS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“July 2, 2025, the Company received an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days”

Coherus Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1).The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. ​ In accordance with Nasdaq Listi”

Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 27, 2025, Silo Pharma, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based o”

FOCUS UNIVERSAL INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“June 30, 2025, Focus Universal Inc. (the “Company”), received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”). The Staff notified the Company that since the Company’s Market Value of Listed Securities has fallen below $35,000,000, the Company no longer satisfies the requirements under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq Listing Rule 5810(c)(3)(C) (the “Compliance Period Rule”), the Company has been provided an initial”

Aqua Metals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 2, 2025, Aqua Metals, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Stock Market, LLC (the “Nasdaq”). The Letter notified the Company that it had fallen below compliance with respect to the continued listing standard set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules because the closing bid price of the Company’s common stock over the previous 30 consecutive trading-day period had fallen below $1.00 per share. The Letter states that due to the fact that the Company has effected a reverse stock split over the prior one-year period, the Company is not eligible”

ATIF Holdings Ltd received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 30, 2025, ATIF Holdings Limited (the “Company”) received a delinquency notification letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) due to the failure of the Company’s common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 29, 2025, to regain compliance. To regain compliance, prior to December 29, 2025, the closing bid price of the Company’s ordinary shares must be at”

iPower Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“July 2, 2025, the Company received formal approval from Nasdaq granting it an additional 180 days, or until December 29, 2025 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If at any time before the Compliance Date the closing bid price for the Company’s Common Stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation that it has regained compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Staff will prov”

FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 1, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive trading days (the “Notice”), as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed a”

Modular Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 30, 2025, Modular Medical Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 29, 2025, in whic”

CIMG Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“June 27, 2025, CIMG Inc. (Nasdaq: IMG) (the “Company”) received a delist determination letter from Nasdaq (“Nasdaq Delist Determination Letter”). On January 13, 2025, February 19, 2025 and May 19, 2025, Nasdaq notified the Company that it did not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-K for the year ended September 30, 2024 (the “Initial Delinquent Filing”), and its Forms 10-Q for the periods ended December 31, 2024, and March 31, 2025 (the “Forms 10-Q”), respectively. As previously disclosed, Nasdaq had g”

Brand Engagement Network Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A), 5550(a)).

“July 1, 2025, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that it has been granted an extension of 180 calendar days (the “Extension”), or until December 29, 2025, to regain compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a). If, at any time before December 29, 2025, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has regained compliance with the Minimum Bid Price Requirement (unless Nas”

TEN Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 30, 2025, TEN Holdings, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In”

Vaxart, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5815(a)(1)(B)(ii)(d)).

“to timely request a hearing by July 8, 2025, then the Hearings Department will take action to follow procedures to delist the Company’s common stock. The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series and is considering all options with regard to its stock listing, including efforts to regain compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will stay delisting but will not stay the tra”

Ocugen, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 1, 2025, Ocugen, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until December 29, 2025, to regain compliance with the minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously reported, on December 31, 2024, Nasdaq notified the Company that for the last 30 consecutive business”

reAlpha Tech Corp. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C), 5810(c)(3)(H)).

“July 1, 2025, reAlpha Tech Corp. (the “Company”) received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the market value of listed securities for the previous 30 consecutive business days, the listing of the Company’s common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires companies listed on The Nasdaq Capital Market to maintain a minimum market value of listed securities of at least $35 million (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule”

BP PRUDHOE BAY ROYALTY TRUST received a nyse delisting notice notice regarding minimum bid price (rules 802.01C).

“June 30, 2025, the NYSE announced the suspension of trading of the Units due to non-compliance with Rule 802.01C of the NYSE Listed Company Manual, effective as of the close of trading on June 30, 2025, and announced that it was initiating proceedings to delist the Units. As a result of the NYSE suspension of trading, the Units began trading on July 1, 2025, under the symbol “BPPTU” on the Pink Limited Market (“OTC Pink”), which is operated by OTC Markets Group, Inc. To be quoted on OTC Pink, a market maker must sponsor the security and comply with SEC Rule 15c2-11 before it can initiate a quo”

ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding other (rules 5605(c)(2)(A), 5605(c)(4), 5605(c)(2), 5605).

“mittee effective July 19, 2025, the day following the Company’s 2025 Annual Meeting. In response to the Company’s notification of Ms. Abenante’s appointment to the Board, on June 25, 2025, the Company received a letter from Nasdaq informing the Company that it was now in compliance with Nasdaq Rule 5605(c)(2) and that the matter is now closed. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements”

Unity Biotechnology, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). Accordingly, Nasdaq, pursuant to its discretionary authority under Listing Rules 5101 and IM-5101-1, notified the Company that, unless the Company requests an appeal of these matters, trading of the Company’s common stock will be suspended at the opening of”

Unity Biotechnology, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, IM-5101-1, 5450(b)(1)(A), 5450(a)(1)).

“urities on Nasdaq is no longer warranted. The Staff also cited its prior notification to the Company on March 14, 2025, as previously reported, that the Company was out of compliance with the minimum $10,000,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), as previously disclosed by the Company. In addition, as previously reported, on June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, whic”

Currenc Group Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(a)(1), 5450(b)(2)(A), 5810(c)(3)).

“June 30, 2025, Currenc Group, Inc. (the “Company”) received two letters from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we are not in compliance with Nasdaq Listing Rules 5450(a)(1) and 5450(b)(2)(A). In the Notice, the Nasdaq Listing Qualifications Department notified us that, for the 30 consecutive business day period between May 14, 2025 through June 27, 2025, our ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), had: (a) not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Global Market pursuan”

Currenc Group Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5450(b)(2)(A), 5810(c)(3)).

“June 30, 2025, Currenc Group, Inc. (the “Company”) received two letters from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we are not in compliance with Nasdaq Listing Rules 5450(a)(1) and 5450(b)(2)(A). In the Notice, the Nasdaq Listing Qualifications Department notified us that, for the 30 consecutive business day period between May 14, 2025 through June 27, 2025, our ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), had: (a) not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Global Market pursuan”

DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“June 23, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum Market Value of Listed Securities (“MVLS”) of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Na”

IMMUNIC, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“June 27, 2025, Immunic, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until December 24, 2025 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of the Initial”

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 27, 2025, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In”

Wetouch Technology Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“June 26, 2025, Wetouch Technology Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq had reviewed and accepted the Company’s plan of compliance relating to the Company’s noncompliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. As previously disclosed, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024, and its Quarterly Report on Form 1”

Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 23, 2025, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price”

GENCOR INDUSTRIES INC received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“June 24, 2025, the Company received a letter (the “Extension Notice”) from the NYSE, informing the Company that the NYSE accepted the extension request, granting the Company a plan period through August 19, 2025 (the “New Cure Deadline”) to submit its delinquent reports. NYSE staff will review the Company periodically for compliance with adherence to the milestones in the plan, and if the Company does not make progress consistent with the plan during the plan period or if the Company does not complete its delinquent reports by the end of the maximum 12-month cure period on December 30, 2025, N”

SCYNEXIS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 20, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 30 consecutive business days, the closing bid price for SCYNEXIS’s common stock was below the $1.00 per share minimum required for continued listing on the Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1). The letter from Nasdaq has no immediate effect on the listing of SCYNEXIS’s common stock on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), SCY”

Royalty Management Holding Corp received a nasdaq compliance regained notice regarding shareholders (rules 5620).

“June 25, 2025, Royalty Management Holding Corporation (or the “Company”) received a letter from the Nasdaq Stock Market indicating that regained compliance with Listing Rule 5620 that requires an annual meeting of shareholders. With the Company’s proxy filed on June 6, 2025, and its annual meeting of shareholders held on June 24, 2025, the Nasdaq Stock Market has determined that the Company has complied with this rule, and this matter is now closed. On June 26, 2025, the Company released a press release notifying the public of its regained compliance with the Nasdaq Stock Market. A copy of the”

Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 20, 2025, Rani Therapeutics Holdings, Inc. (“Company”) received a letter (“Notice”) from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Under Na”

ProPhase Labs, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(ii)).

“June 25, 2025, the Company received a letter from the Nasdaq staff advising that the Company had been granted a 180-day extension to December 22, 2025 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and December 22, 2025, and will consider available options to resolve the deficiency to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the Company’s Class A ordinary shares must have a”

NOODLES & Co received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“On June 24, 2025, Noodles & Company (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Global Select Market.”

SUTRO BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 20, 2025, Sutro Biopharma, Inc. (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until December 17, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share”

Hall of Fame Resort & Entertainment Co received a nasdaq delisting notice notice regarding shareholders (rules 5620(a)).

“June 18, 2025, the Company received a delisting notice from the Listing Qualifications Department of Nasdaq notifying the Company that it has initiated delisting procedures based on a representation from the Company that it will not hold an annual meeting of shareholders on or prior to June 30, 2025. The failure to hold an annual meeting of shareholders within twelve months from the end of the Company’s fiscal year-end is a requirement by Nasdaq Listing Rule 5620(a). If the Company does not appeal the delisting determination to a Hearing Panel pursuant to Nasdaq Listing Rule 5800 Series, tradi”

Allied Gaming & Entertainment Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“June 18, 2025, Allied Gaming & Entertainment Inc. (the “Company”) received a notice (the “Notice”) from the staff of The Nasdaq Stock Market (“Staff”) indicating that, based on the Company’s non-compliance with Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end, the Staff determined to initiate procedures to delist the Company’s securities unless the Company requests an appeal to a Nasdaq Hearings Panel (the “Panel”) by June 25, 2025. Additionally, the Staff notified the Company that its”

Allied Gaming & Entertainment Inc. received a nasdaq delisting notice notice regarding other (rules 5620(a)).

“June 18, 2025, Allied Gaming & Entertainment Inc. (the “Company”) received a notice (the “Notice”) from the staff of The Nasdaq Stock Market (“Staff”) indicating that, based on the Company’s non-compliance with Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end, the Staff determined to initiate procedures to delist the Company’s securities unless the Company requests an appeal to a Nasdaq Hearings Panel (the “Panel”) by June 25, 2025. Additionally, the Staff notified the Company that its”

Momentus Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“June 24, 2025, Momentus Inc. (the “Company”) announced that it has received a letter from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market (“Nasdaq”) providing written confirmation that the Company has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). As previously reported, on January 12, 2025, the Company had received a letter issued by the Panel granting the Company’s request to continue its listing on The Nasdaq Capital Market until”

Laser Photonics Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 22, 2025, the Company received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the “Initial Delinquent Filing”), the Company does not comply with Nasdaq’s Listing Rule Rule 5250(c)(1) (the “Rule”) for continued listing. Nasdaq stated that in accordance with its letter dated April 16, 2025, the Company had until June 16, 2025, to submit a”

CLEARONE INC received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“June 24, 2025, the Company received a letter from Nasdaq advising that the Company's Common Stock had traded above $1.00 per share for the ten consecutive trading days ending June 24, 2025 and had regained compliance with the Minimum Bid Price Requirement and the Company would not be delisted. As of June 24, 2025, the Company is in full compliance with all continued listing standards of the Nasdaq Capital Market.”

CLEARONE INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 20, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") informing the Company that because the closing bid price for the Company's Common Stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company was given a period of 180 calendar days from June 20, 2024, or until December 1”

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“June 18, 2025, the Company received a written notice (the “June Notice”) from Nasdaq indicating that the Company no longer complies with Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)” and, together with Rule 5550(a)(2), the “Listing Rules”) requiring that listed securities maintain a minimum bid price of $0.10 per share based upon the Company’s closing bid price for the last 10 consecutive trading days prior to the June Notice. The June Notice also stated that the noncompliance with Rule 5450(a)(1) serves as an additional basis for delisting the Company’s securities from Nasdaq, and that th”

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 21, 2025, Graphjet Technology (the “Company” or “Graphjet”) received written notice (the “February Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company no longer complied with Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”) requiring that listed securities maintain a minimum bid price of $1.00 per share based upon the Company’s closing bid price for the 32 consecutive days prior to the February Notice. Additionally, the February Notice confirmed that Rule 5550(a)(2) grants the Company 180 calendar days, or until Augus”

SMITH MICRO SOFTWARE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 23, 2025, Smith Micro Software, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that as a result of the closing bid price of the Company’s common stock (“Common Stock”) for the last 30 consecutive business days having been below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) the Company was not in compliance with the Minimum Bid Price Requirement (the “Minimum Bid Price Notice”). The Minim”

SUPERIOR INDUSTRIES INTERNATIONAL INC received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“June 17, 2025, Superior Industries International, Inc. (“Superior” or the “Company”) received a written notice from the New York Stock Exchange (the “NYSE”) that the Company no longer satisfies the continued listing compliance standards set forth under Section 802.01C of the NYSE Listed Company Manual (the “Manual”) because the average closing price of the Company’s common stock, par value $0.01 per share (the “Common Stock”) was less than $1.00 per share over a consecutive 30-trading day period (the “Share Price Deficiency Notice”). Pursuant to Section 802.01C of the Manual, the Company has a”